Key facts
- SnapDNA’s last known valuation is $28.0M (Apr 2021).
- It has raised $4.8M; the latest was Angel (individual) ($500K) in Mar 2025.
- Notable investors include Plug and Play Tech Center, In-Q-Tel, Aria Emiko (Investment), Accel Impact Ventures, Advanced Industries Accelerator — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for SnapDNA
- ·The full record, as it builds
Funding rounds
No funding rounds for SnapDNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SnapDNA
Developer of on-site pathogen testing technology designed to create a rapid pathogen detection system for food processing facilities. The company's analysis eliminates the time taking procedure of food pathogen testing and reduces the number and severity of outbreaks of pathogens, enabling clients to lower production costs and offer fresh and safe food.
- Sector
- Healthcare
- HQ
- Broomfield, CO, United States
- Founded
- 2011
- Employees
- 7
- Website
- snapdna.com/
- Ownership
- Privately Held (backing)
SnapDNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SnapDNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SnapDNA in its N-PORT filings yet. We sweep new filings monthly.